Ultrasound-Mediated Biotransfection of Engineered Bone Marrow Mesenchymal Stem Cells in Treated Bone Defects through Intracellular Cavitation.

ABSTRACT: The lack of stem cells and difficulty in osteogenic differentiation are the primary challenges to treating bone defects. Stem cell gene therapy can efficiently replenish the number of stem cells and facilitate bone differentiation, but its security and efficacy remain challenging. The traditional ultrasound-targeted microbubble destruction (UTMD) technology with extracellular cavitation for gene transfection is safe but inefficient. Consequently, gas vesicles extracted from Halobacterium NRC-1 are used as carriers, incorporating nuclear localization signal, polyethyleneimine, and plasmid bone morphogenetic protein 2 (pBMP2). Then followed by internalization into bone marrow mesenchymal stem cells (BMSCs) to produce engineered BMSCs, which exhibit significant capacity of lysosome escape and

SUBMITTER: Xu Z 

PROVIDER: S-EPMC12561189 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature